Related Experiment Video

Updated: Sep 11, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Expression of the multidrug resistance gene in human tumors

R Kim1

  • 1Department of Surgery, Hiroshima University, Japan.

Hiroshima Journal of Medical Sciences
|September 1, 1990
PubMed

Insights

This study investigated the MDR1 gene in human solid tumors and adriamycin resistance. Immunohistochemical analysis for P-glycoprotein showed higher sensitivity than MDR1 mRNA levels in predicting resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • The MDR1 gene, encoding P-glycoprotein, is a key factor in MDR.
  • Adriamycin resistance in solid tumors requires better diagnostic markers.

Purpose of the Study:

  • To investigate MDR1 gene expression in human solid tumors.
  • To correlate MDR1 expression with adriamycin resistance.
  • To compare the sensitivity of RNA dot blot and immunohistochemical analysis for P-glycoprotein detection.

Main Methods:

  • Analysis of 40 fresh human surgical tumor specimens.
  • RNA dot blot assay for MDR1 mRNA expression.
  • Immunohistochemical staining using a monoclonal antibody against P-glycoprotein.

Main Results:

  • MDR1 mRNA levels were elevated in 11 out of 40 tumors.
  • P-glycoprotein expression was detected in 18 out of 40 tumors via immunohistochemistry.
  • A significant correlation was observed between MDR1 mRNA levels and P-glycoprotein expression.
  • Two adriamycin-resistant tumors showed negative MDR1 transcript but positive P-glycoprotein staining.

Conclusions:

  • Immunohistochemical analysis is more sensitive for detecting P-glycoprotein expression than MDR1 mRNA levels.
  • Adriamycin resistance is multifactorial and can be partly attributed to increased MDR1 gene product.
  • P-glycoprotein expression is a valuable indicator for adriamycin resistance in solid tumors.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System05:06

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...